After months of speculation about Gilead Sciences Inc.'s need to accelerate its business development activities to augment its antiviral products portfolio, it finally pulled the trigger on a major acquisition last week. The proposed $11.9 billion acquisition of Kite Pharma Inc., a leader in chimeric antigen receptor (CAR) and engineered T-cell receptor development (TCR), will vault the company into the white-hot immuno-oncology (I-O) space.